Clinical trials: Hepatic Function Abnormal
Neoplasms, Lymphomas
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Background: Belinostat is an experimental cancer treatment drug that works by helping to turn on genes that limit cell growth and survival of cancer cells. These genes are often switched off in tumors.
- Trial name
- NCT01273155
- Testing
- Belinostat
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Graves Disease, Graves Ophthalmopathy
Liver Function After Intravenous Methylprednisolone Administration
Graves' orbitopathy (GO) is a characterized by orbital soft tissue inflammation and oedema associated with glycosaminoglycan deposition and fibrosis. The most frequent cause is Graves' disease.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Liver Diseases, Liver Failure
- Trial name
- NCT03667157
- Testing
- every week IVMP therapy, very high doses IVMP therapy
- Volunteers
- 68 people
- Sponsor
- Medical University of Warsaw
Advanced Solid Tumors, Hematologic Malignancies
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate hepatic impairement or severe hepatic…
- Trial name
- NCT01912222
- Testing
- IXAZOMIB
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hepatic Dysfunction Transient, Renal Function Disorder
Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum
The purpose of this study is to compare the effect of TEAS pretreatment and treatment on hepatic and renal dysfunction induced by pneumoperitoneum in patients undergoing laparoscopic surgeries.
- Trial name
- TRIP (NCT02013596)
- Testing
- TEAS pretreatment, TEAS treatment
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Zhihong LU
ITP - Immune Thrombocytopenia
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
- Trial name
- NCT07093606
- Testing
- Eltrombopag
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH)
How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH), Type 1 Diabetes Mellitus
- Trial name
- AGL14 (NCT07133854)
- Testing
- Imaging PET/MRI, Stable isotope infusions, meal test
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Cholangiocarcinoma, Cirrhosis
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
This phase I trial studies the side effects and the best dose of radiation therapy in treating patients with hepatocellular carcinoma, cholangiocarcinoma, or cancer that has spread from the original (primary) tumor to the liver…
- Conditions
- Cholangiocarcinoma, Cirrhosis, Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT02626312
- Testing
- Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Radiation Therapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Organ Transplantation, Liver Dysfunction
Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers
Liver transplantation (LT) is a highly effective treatment for end-stage liver disease and early-stage primary liver cancer. As such, the demand for donor livers greatly exceeds supply; in 2021 in France, 12.9% of patients on the…
- Conditions
- Organ Transplantation, Liver Dysfunction, Liver Diseases
- Trial name
- TRANSPERF (NCT06950398)
- Testing
- NMP viability testing
- Where
- 6 sites in France
- Volunteers
- 99 people
- Sponsor
- Rennes University Hospital
Stem Cell Transplantation, Liver Diseases
Hepatic Artery Infusion of CD34+ Cells
The primary objective is to determine whether donor stem cells administered via hepatic artery infusion can produce liver cells in patients with severe hepatic dysfunction post stem cell transplantation (SCT) and the safety of…
- Trial name
- NCT00062543
- Testing
- Hepatic artery infusion of CD34+ cells, Cobe Spectra
- Sponsor
- M.D. Anderson Cancer Center
Transthyretin (TTR) Amyloid Cardiomyopathy, Cardiac Amyloidosis
Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive infiltrative cardiomyopathy caused by the deposition of misfolded transthyretin protein within the myocardium.
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy, Cardiac Amyloidosis, Cardiomyopathies, Wild-Type Transthyretin Cardiac Amyloidosis
- Trial name
- LICA2025 (NCT07766135)
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Messina
End Stage Liver Disease, Jaundice
SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury.
- Conditions
- End Stage Liver Disease, Jaundice, Liver Dysfunction, Portal Hypertension
- Trial name
- NCT06173947
- Testing
- FibroScan® Expert 630
- Where
- China
- Volunteers
- 411 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Diseases, Liver Dysfunction
Monitoring the HePAtological TOXicity of Drugs (HePATOX)
Several drugs and chemotherapies seem to have an impact on the hepatological system. This study investigates reports of hepatological toxicities, including the International classification of disease ICD-10 for treatments in the…
- Conditions
- Liver Diseases, Liver Dysfunction, Liver Failure, Hepatotoxicity
- Trial name
- HePATOX (NCT03833297)
- Testing
- Drugs inducing hepatological toxicity
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Lymphoma, Small Intestine Cancer
S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049400
- Testing
- BMS-247550
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- SWOG Cancer Research Network
Infection, Liver Dysfunction
Temocillin Pharmacokinetics in Paediatrics
Temocillin (6-methoxy-ticarcillin) is a beta-lactam antibiotic with exceptional resistance to most beta-lactamases. In this context, it is now increasingly used as carbapenem-sparing antibiotic in patients with suspected…
- Conditions
- Infection, Liver Dysfunction, Urinary Tract Infection
- Trial name
- TEMOPEDI (NCT02260102)
- Testing
- Temocillin
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Université Catholique de Louvain
Hepatic Insufficiency, Healthy
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.
- Trial name
- NCT01111318
- Testing
- BI 10773
- Where
- Romania
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis B
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
- Trial name
- NCT07600788
- Testing
- AHB-137 injection
- Where
- 5 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
Hepatic Function Abnormal
A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment
In human, metabolic hepatic clearance represents a significant part of the total clearance of fexinidazole and could be decreased in patients with liver impairment, leading to some overexposure, and conversely, the formation of…
- Trial name
- NCT05607173
- Testing
- Fexinidazole (HOE239)
- Where
- 2 sites in Bulgaria, France
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Sanofi
Liver Dysfunction, Immune Suppression
Optimizing HBV Management During Anti-CD20 Antibodies
Hepatitis B virus (HBV) reactivation is common during anti-CD20 containing chemotherapy, even in HBsAg-negative patients with only prior HBV exposure.
- Conditions
- Liver Dysfunction, Immune Suppression, Hepatitis B
- Trial name
- NCT03155984
- Testing
- Anti-CD20 antibody
- Where
- Hong Kong
- Volunteers
- 83 people
- Sponsor
- The University of Hong Kong
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency
Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency
This was the first clinical study of SBC-102 (sebelipase alfa) for the treatment of Lysosomal Acid Lipase (LAL) Deficiency. It was an open-label dose escalation study in adult participants with liver dysfunction due to LAL…
- Conditions
- Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
- Trial name
- NCT01307098
- Testing
- Sebelipase alfa 0.35 mg/kg, Sebelipase alfa 1 mg/kg, Sebelipase alfa 3 mg/kg
- Where
- 7 sites in United States, Czechia and 2 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Diabetes, Healthy
A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function
This trial was conducted in Europe. The aim of this clinical trial was to evaluate if the pharmacokinetic and safety profiles of NN1250 (insulin degludec) are altered to such an extent that the dose should be adjusted in subjects…
- Trial name
- NCT00976326
- Testing
- insulin degludec
- Where
- Slovakia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S